Actas dermo-sifiliográficas
-
Actas Dermosifiliogr · Jul 2017
Randomized Controlled Trial Multicenter Study Comparative StudyComparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study.
Ixekizumab demonstrated greater efficacy than placebo and etanercept in UNCOVER-3. Subgroup analysis of Latin American patients was performed. We report 12-week and 60-week data. ⋯ In Latin American patients, both ixekizumab dosing regimens demonstrated greater efficacy than etanercept for treating psoriasis over 12 weeks. The safety profile of ixekizumab through 60 weeks was well tolerated and consistent with the overall profile.
-
Actas Dermosifiliogr · Nov 2013
Multicenter Study Observational StudyDemographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study.
Psoriasis is associated with a deterioration in the health-related quality of life (HRQoL) of affected patients. The aim of this study was to assess the HRQoL of patients with moderate-to-severe psoriasis. ⋯ The principal factor related to HRQoL in patients with psoriasis is the severity of the disease.
-
Actas Dermosifiliogr · Oct 2013
Multicenter Study Comparative Study Observational StudyImpact of active and stable psoriasis on health-related quality of life: the PSO-LIFE study.
The aim of this study was to assess the impact of psoriasis on health-related quality of life (HRQOL) using different questionnaires. ⋯ The impact of psoriasis on HRQOL is higher in patients with active disease. The PSO-LIFE questionnaire showed a greater tendency to discriminate between active and stable psoriasis than either the DLQI or the PDI. PSO-LIFE scores correlated significantly with lesion site and disease severity as measured by PASI.
-
Actas Dermosifiliogr · Jan 2013
Multicenter StudyImpact of atopic dermatitis on health-related quality of life in Spanish children and adults: the PSEDA study.
Atopic dermatitis (AD) affects both children and adults. The main symptom of this disease is pruritus, which impacts health-related quality of life (HRQOL). The aim of this study was to evaluate the impact of AD on the lives of children and adults with this disease. ⋯ AD affects HRQOL in both children and adults and its impact is correlated with the presence and intensity of pruritus.
-
Actas Dermosifiliogr · Sep 2011
Multicenter Study[Validation of the Spanish Version of the Itch Severity Scale: the PSEDA study].
The Itch Severity Scale (ISS) facilitates objective assessment of the intensity of pruritus. The aim of this study was to validate a Spanish version of the ISS in patients with atopic dermatitis. ⋯ The Spanish version of the ISS is feasible, valid, sensitive to change, and displays good reliability based on internal consistency in both children and adults.